Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to cure cancers. Using its proprietary Fast-Clear™ Linker technology, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation radiopharmaceuticals. In preclinical studies, the company has shown the ability to precisely target and effectively kill solid tumor cells while minimizing the impact to healthy tissue. Fusion’s lead program, FPI-1434, is currently in Phase 1 development.
With a proprietary discovery platform, Fusion is actively in-licensing targeting molecules and forming strategic partnerships to expand its pipeline of cancer therapies. For more information, please visit www.fusionpharma.com or contact email@example.com.